Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SSB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SSB Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ELISA and SPR binding assays. |
View SSB Products |
| Gene Delivery | SSB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View SSB Products |
| Benchmark Ab | Anti-SSB Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View SSB Products |
| Validator | SSB siRNA Set For target knockdown verification and specificity profiling. |
View SSB Products |
| Related Target A | SSA (Ro60) Synergistic autoimmune marker; frequently co-analyzed with SSB in Sjögren's syndrome panels. |
View SSA Products |
| Related Target B | TRIM21 (Ro52) E3 ubiquitin ligase co-targeted in autoimmune profiling and intracellular antibody-mediated degradation assays. |
View TRIM21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Autoantibody assay cross-reactivity | Human recombinant SSB protein strictly verified by mass spectrometry to eliminate host cell protein contamination. |
| Epitope mapping and structural integrity | HEK293 expressed recombinant SSB preserving native post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SSB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SSB therapeutics is intensifying, with major players shifting focus from traditional diagnostics to novel tolerogenic therapies and targeted oncology interventions. As first-generation therapies reach the clinic, the next wave of R&D is targeting antigen-specific immune tolerance to neutralize anti-SSB autoantibodies without systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Tolerogenic Vaccines | Anokion, Cour Pharmaceutical | Sjögren's Syndrome, SLE | High-purity recombinant SSB protein for antigen-specific tolerance screening. |
| Monoclonal Antibodies | Immunology Therapeutics | Autoimmune Diseases | Affinity determination and epitope mapping using sequence-verified antigens. |
| siRNA / RNAi | Alnylam, Arrowhead | Oncology (SSB-overexpressing tumors) | Target knockdown validation using sequence-specific siRNA sets. |